Shares of Abbott Laboratories are rising and those of Reckitt Benckiser are gaining in London trading Friday, a day after a jury cleared the two infant formula makers of liability for a boy's debilitating intestinal disease.
The ruling by a Missouri state court jury is a rare legal win for Abbott Laboratories, maker of Similac formula, and Reckitt, which owns Enfamil formula maker Mead Johnson, following their losses in similar trials.
UBS called the win "the first victory for the two companies" in a state case involving necrotizing enterocolitis (NEC), a life-threatening disease that affects the colon and intestine.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.